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While industrialized countries’ stem cell research will be transferable to the developing world, research con-
ducted by developing countries offers the potential to target innovation to local context, make treatments
more affordable, and aid in economic development. India demonstrates that stem cell research and develop-
ment (R&D) is not confined to industrialized countries and has begun to harness stem cells to address its own
health needs.An epidemiological transition is occurring in developing coun-
tries. Once thought of as ‘‘Western diseases,’’ the prevalence
of noncommunicable diseases such as diabetes, cardiovascular
disease, and cancer are rapidly increasing in low and middle
income countries. While still an emerging field of medicine,
stem cell R&D has the potential to help developing countries
treat increasing noncommunicable disease rates. Until recently,
stem cell research has been concentrated in relatively few coun-
tries, largely the most affluent and technologically advanced.
Several developing countries, however, now actively participate
in the stem cell field, producing new knowledge and promising
clinical trials. Our previous work supports the belief that regener-
ative medicine, a field in which stem cells act as key building
blocks, could help address developing countries’ health needs
and identifies three top regenerative medicine applications for
the developing world: novel methods of insulin replacement
and pancreatic islet regeneration for diabetes, autologous cells
for the regeneration of heart muscle, and immune system en-
hancement and novel vaccination strategies (Greenwood et al.,
2006). Certainly the health needs of the developing world are
great: for example, 80% of chronic disease deaths occur there,
according to a 2005 World Health Organization report, and this
rate is expected to rise in the coming years (Boutayeb and
Boutayeb, 2005). While stem cell research conducted in industri-
alized countries will, in many cases, be transferable to the devel-
oping world, research in the developing world tailors innovation
based on the local context in order to make treatments more
affordable and contributes toward the economic development
of these countries. This targeting approach is especially relevant
in emerging economies like India and China that have the poten-
tial to conduct their own stem cell research and therapy develop-
ment. To better understand the potential developing countries
have for building their own stem cell R&D capacity, we present
here the case of stem cell R&D in India, based in part on inter-
views with 38 Indian experts on stem cell research and therapies
from research institutes, hospitals, private firms, universities,
and government agencies (see Table S1 and the Supplemental
Data, available online, for details on methodology).
India is one of few developing countries to have begun work
on novel stem cell technologies and therapies. We believe that
India has strengths in stem cell research geared toward develop-
ing applications to meet its health needs and budget; it also has
the potential to make important global contributions to this
emerging field. The experience in India shows how the develop-ing world can harness the potential of stem cell research and
make an active contribution to the development of this field.
Current State of Stem Cell Research in India
Indian authors have, in recent years, sharply increased their
publications in stem cell research in international peer-reviewed
journals. At the beginning of the new millennium, Indians auth-
ored hardly any stem cell publications, but by 2007 they were
authoring around 100 stem cell papers a year listed in the Web
of Science alone. Indians have also started to develop stem
cell lines, including at least three human embryonic stem cell
(hESC) lines to date (see UK Stem Cell Bank and National Insti-
tutes of Health (NIH) Human Embryonic Stem Cell Registry).
Two hESC lines derived by the Jawaharlal Nehru Centre for
Advanced Scientific Research (JNCASR), in Bengaluru, are now
accepted for deposition and distribution by the UK Stem Cell
Bank (see the UK Stem Cell Bank website). The cell lines, derived
from low-quality embryos discarded post-IVF procedures, will
be part of the International Stem Cell Initiative 2 (ISCI2) project
to identify the common genetic changes that occur in hESC lines
on prolonged culture. This will be the first time that India is rep-
resented on an ISCI project. Alka Sharma, principal scientific
officer of India’s Department of Biotechnology (DBT), believes
there are more than 30 research institutes, hospitals, and firms
involved in stem cell research in India (Sharma, 2006). These
sites include large public hospitals such as the All India Institute
of Medical Sciences (AIIMS), in Delhi; dedicated private compa-
nies such as LifeCell, in Chennai; and research institutes such
as the National Centre for Cell Sciences (NCCS), in Pune (see
Figure 1 for geographic locations). Their activities are varied and
include basic research, clinical trials, treatments, and service
provision.
Research Institutes
Public research institutes are the largest group active in stem cell
research within India. Some institutes focus primarily on basic
research. JNCASR, for example, studies ESC differentiation
into cardiovascular cells. Other institutes balance basic research
with applied activities such as animal modeling, clinical trials, or
pilot treatments. NCCS has conducted animal and preclinical
analyses of bone marrow stem cell injections for pancreatic re-
generation. Research efforts from this institute succeeded in res-
cuing mice with experimentally induced diabetes after a 30 day
follow up (Banerjee et al., 2005), and scientists at NCCS hope
to extend this work to an autologous clinical trial in humanCell Stem Cell 3, July 2008 ª2008 Elsevier Inc. 11
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clinicians, scientists, and patients to act as a platform for the trial,
a process they estimate will take 3–4 years. Others, such as the
Central Leather Research Institute (CLRI), hope to transfer their
current stem cell research to the private sector. CLRI is currently
focused on engineering tissue by seeding scaffolds with stem
cells. Their general business model is to conduct the basic
research and find a private partner for further development.
This is a model they have successfully applied in the past, as
illustrated in their transfer of collagen sheet wound dressing
technology to a local company, Eucare Pharmaceutical Pvt.
Ltd. (Chennai), for production.
Hospitals and Clinics
Unlike India’s biotechnology sector as a whole (Frew et al.,
2007), few Indian companies are involved in stem cell research.
Instead, Indian hospitals and clinics are key players. India’s large
research-intensive hospitals, such as AIIMS, conduct basic and
applied research and have clinical trial and pilot treatment capa-
bilities. This combination of resources creates a bridge between
research and therapy and makes hospitals pivotal for Indian
stem cell innovation. AIIMS works on a wide spectrum of clinical
applications in cardiology, ophthalmology, neurology, and he-
matology and also carries out basic research on, for example,
stem cells and biopolymers aimed at treatments for orthopedic,
ocular, and skin diseases. Christian Medical College and Hospi-
tal (CMC) in Vellore is founding a center for stem cell research in
collaboration with DBT to promote translational research with
stem cells. Sankara Nethralaya, an eye hospital based in Chen-
nai, has similarly built a research building to house the Kamal-
nayan Bajaj Institute of Research in Vision and Ophthalmology.
Opening in September 2008, stem cell research will be a key
focus of this new building, with projects covering diverse areas
such as corneal stem cells, cancer stem cells, and the use of
stem cells in tissue engineering. Stempeutics, in Bengaluru, is
the research arm of Manipal Education and Medical Group
(MEMG). Its efforts are designed to divide resources between
basic and clinical research. Employing both scientists and clini-
cians, Stempeutics sees itself as a bridge between the two
groups. Areas of basic research include mesenchymal stem
cells, cancer biology, and cardiovascular research, while clinical
trials are underway for myocardial infarction, critical limb ische-
Figure 1. Locations of Main Stem Cell Activities in India12 Cell Stem Cell 3, July 2008 ª2008 Elsevier Inc.mia, cerebral stroke, and multiple sclerosis. Stempeutics has
also recently established an R&D lab in Malaysia, joining hands
with one of Malaysia’s largest healthcare groups, KPJ Health-
care Berhad. Many hospitals have conducted pilot treatments
in areas such as cardiac, spinal, and ocular regeneration. AIIMS
has been involved in a variety of stem cell pilot therapies for
disorders ranging from liver cirrhosis (Sharma et al., 2006) to
nonischemic dilated cardiomyopathy (Narang et al., 2006).
The best example of a homegrown Indian stem cell treatment
that addresses local health needs is the ocular surface recon-
struction method developed at L.V. Prasad Eye Institute (LVPEI),
a nonprofit hospital in Hyderabad. LVPEI clinicians saw patients
suffering from severe ocular surface disease that they were un-
able to treat with traditional corneal transplantation methods.
Many of these injuries affected children under 15 and were often
caused by chemical burns from accidental exposure to materials
frequently used in Indian homes. Lime, which is a highly alkaline
substance and a key ingredient in paan (a popular Indian stimu-
lant and digestive), was the leading cause of chemical burns
(Fatima et al., 2007). In reaction to patient need, LVPEI scientists
and clinicians explored potential stem cell-based treatments and
ultimately developed a time- and cost-effective ocular surface
reconstruction method. Still an ‘‘extended clinical trial,’’ LVPEI
has performed the treatment on more than 500 patients with
a success rate of 70% (Sangwan et al., 2003, 2005). LVPEI offers
this treatment irrespective of income and is supported by DBT,
the government of India, the Hyderabad Eye Reserach Founda-
tion, and the Champalimaud Foundation. To date, at least half
the patients treated have been nonpaying.
Companies
Most Indian companies that can be classified as working within
the field of stem cells are primarily involved in umbilical cord
blood banking, an established practice that provides the industry
with a commercial base. Some of these companies are begin-
ning to develop stem cell-based treatments as well, often linked
to Indian health needs. The Indian firms LifeCell (in Chennai),
CryoStemCell (in Bengaluru), and Reliance Life Sciences (in
Mumbai) have all established umbilical cord blood banking facil-
ities. Many of these firms also have international links. LifeCell is
planning to expand into the Middle East and South Asia and has
a technology licensing agreement with the firm Cryo-Cell Inter-
national, a company from the United States. LifeCell has also
opened a stem cell therapy facility at Sri Ramachandra Medical
College and Research Institute, in Chennai. The potential to col-
lect umbilical cord samples from India’s large and ethnically
diverse population recently led to the establishment of a joint
venture, StemCyte India Therapeutics, between another firm
from the United States, StemCyte, and India’s Apollo Hospitals
network and Cadila Pharmaceuticals (Ahmedabad).
Some Indian companies have also begun to develop treat-
ments for various diseases. CryoStemCell, in partnership with
Sri Bhagwan Mahaveer Jain Hospital (in Bengaluru), conducted
a pilot stem cell treatment for Buerger’s disease, a severe form
of peripheral vascular disease, which is relatively rare in the
Western hemisphere but common in India. It represents up to
45%–63% of peripheral arterial disease cases in India but only
0.5%–5.6% in Western Europe (Olin, 2000). Buerger’s disease
causes inflammation of limb arteries, often leading to amputa-
tion and incapacitation of Indian farmers. If successful,
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real health need in India. Reliance Life Sciences is also involved
in treatment development and is investing in an animal facility
to conduct toxicology and preclinical efficacy studies for cell-
based therapies.
Finally, Nich-In Centre for Regenerative Medicine (NCRM), in
Chennai, is not involved in umbilical cord banking but is instead
focused on treatment development within India. NCRM was
started by a group of scientists at Waseda University in Japan,
including one Indian expatriate. A research lab was established
in Chennai in September 2005, due to several perceived advan-
tages in conducting applied research within India. These advan-
tages included India’s large population and vast spectrum of
diseases on which research might be conducted; the substan-
tially lower price of conducting research in India as opposed to
Japan; the fact that Indian scientists speak English, allowing
for article submission for English journals; and, finally, the shorter
timelines for gaining approval to conduct applied research in
India as opposed to Japan. The NCRM business model is to
employ both scientists and clinicians in developing technology
while collaborating with health care delivery systems. Collabora-
tion with Japan is high. NCRM has signed a research memoran-
dum of understanding with Yamanashi University, has started
a nanobiomaterial-based cell culture with the Kawamura Insti-
tute of Chemical Research, and is collaborating with Yamaguchi
University on hematopoietic stem cell research.
Universities
Few Indian universities appear active in stem cell research at
this time. The main exception is the University of Delhi, which,
together with the Indian Institute of Nuclear Medicine and Allied
Sciences, is examining basic mechanisms of stem cell function.
However, many of the hospitals, firms, and research institutes
active in stem cell R&D are also involved in education. Both CMC
and AIIMS are teaching hospitals that provide postgraduate
degrees. Many of India’s research institutes are colocated with a
university and informally train students within their research labs.
Government Support
The Indian government has been a key factor in encouraging
stem cell R&D activity and growth. Stem cell engineering is
seen as an important area for the government and is identified
as a strategic biotechnology area in the DBT’s 2007 Biotechnol-
ogy Strategy (available online). Four government departments
are key supporters of stem cell R&D: DBT, the Indian Council
for Medical Research (ICMR), the Department of Science and
Technology, and the Council of Scientific and Industrial Re-
search. Stem cell R&D promotion is driven largely by the DBT
Stem Cell Taskforce and by ICMR through its affiliated institutes
and regulatory capacity. DBT provides direct funding to targeted
initiatives in this field and supports both infrastructure building
and operational activities such as clinical trials. It has begun
to support large-scale strategic programs, such as a phase III
multicenter trial using bone marrow cells to treat myocardial
infarctions, and sponsors stem cell research centers like the
Centre for Stem Cell Research (CMC, in Vellore) and a soon-
to-be-established stem cell research center in Bengaluru, the
Institute for Stem Cells and Regenerative Medicines. As has
been shown elsewhere for the case of health biotechnology
(Thorsteinsdo´ttir et al., 2004), government support is often key
to capability building within emerging economies.Building Stem Cell R&D on India’s Strengths
India’s capacity to participate in a cutting-edge field such as
stem cell research is, in part, built on skills and infrastructure pre-
viously developed by the nation’s pharmaceutical and biotech-
nology sectors (Kumar et al., 2004). One such skill is the proven
ability of Indian firms to develop process innovations in order to
lower prices (Frew et al., 2007). Innovations that lower process
costs have already occurred in the stem cell field. Researchers
do not necessarily copy blindly the techniques used in devel-
oped countries but create their own cost-efficient cell and tissue
culturing and storage techniques that use fewer disposable de-
vices. Indian companies have also begun to produce materials,
such as growth factors, that are needed in stem cell research
at significantly lower rates.
In addition, India’s pharmaceutical and biotechnology sectors
have helped India develop an expertise in conducting clinical
trials. Bolstering this expertise, India’s large, diverse, and treat-
ment-naive population provides a valuable resource for clinical
trials, especially for rare diseases where the Indian population
could provide sufficient patients for trial groups. As a result, India
has great potential to act as a clinical trial destination of choice
for stem cell therapies. This could help India develop and test
stem cell therapies for a variety of diseases. This strength is likely
to encourage more international ties and joint ventures, a trend
already exemplified in the collaborations of United States/Indian
firm StemCyte India Therapeutics and the Japanese/Indian
venture NCMR.
The cultural acceptability of stem cell therapies will help India
further develop this sector. Unlike the public controversies that
surround ESC research in many other nations, there has been
no strong public objection to ESC research in India. Some
themes in Hindu mythology might help increase Indian accep-
tance of embryonic research practices such as cell or tissue
cloning. For example, in one Indian myth, King Dhritarashtra cre-
ates 100 sons by dividing a fetus into 100 different parts and
growing each in a pot, in effect through cloning. There is also
a potential complementarity between India’s traditional medi-
cine system, Ayurveda, and stem cell therapy. Researchers cur-
rently complement stem cell therapies with Ayurvedic principles
of purging and rejuvenating the body in conjunction with modern
stem cell leukemia treatments. Further synergies could develop
between stem cell therapies and Ayurveda in order to advance
the national experience in this field, as well as giving such thera-
pies a distinctively Indian twist.
Overcoming India’s Stem Cell R&D Challenges
Promoting Linkages
As a translational research field, stem cell development requires
a high degree of linkage between basic and clinical expertise.
India’s most successful research institutes and hospitals, such
as AIIMS and LVPEI, are those that integrate the efforts of
basic scientists with clinicians. Unfortunately, this integration
has historically been weak at most research sites elsewhere in
India. Increasing coherence and connectivity between these dif-
ferent sectors is the cornerstone of India’s new biotechnology
strategy (DBT Strategy, 2007), and specific institutions, as well
as the government, have initiated steps to promote interactions
between basic and clinical stem cell researchers. The construc-
tion of a joint research center between the academic Centre forCell Stem Cell 3, July 2008 ª2008 Elsevier Inc. 13
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Institute of Medical Sciences, both in Hyderabad, is an example
of an Indian institutional initiative aiming to increase clinician/
scientist interaction.
The DBT is promoting improved integration with its stem cell
cluster initiative, which encourages publicly and privately funded
stem cell research groups to share ideas, facilities, and research.
Four clusters are already established: around the CMC in Vellore,
the NCCS in Pune, in Bengaluru, and in Hyderabad. The project
is expected to expand and promote an additional cluster in Delhi
(see the DBT strategy report, available online). The DBT also
supports India’s Stem Cell Research Forum in partnership with
Stempeutics, Bengaluru, which encourages knowledge flow
and linkages by acting as a platform for Indian scientists to dis-
cuss ideas and network with one another. The DBT is also plan-
ning to establish a new breed of institutions, such as the stem cell
institute it is building in Bengaluru, which will be designed with
a strong bias for integrating science and translation and for pro-
ducing personnel skilled to carry out entrepreneurial activities.
Strengthening Training
For India to increase its stem cell research capacity, it will need
to strengthen the quality of its current scientific education. The
DBT is helping Indian scientists gain expertise abroad by offering
overseas stem cell fellowships and travel bursaries for confer-
ences. Research institutes are increasing their involvement in
training through postgraduate supervision and by coordinating
workshops, such as the stem cell training workshops currently
run by JNCASR in partnership with the NCBS, both in Bengaluru.
Universities are also becoming more involved in stem cell train-
ing programs, such as Manipal University’s efforts to establish
an Institute of Regenerative Medicine with a related graduate
program in the summer of 2007. NCMR, in collaboration with
Acharya Nagarjuna University (in Chennai), launched a stem
cell PhD program in April 2008. The program will be focused
on bringing clinicians together with scientists. Indians can also
strengthen their capacity for stem cell research by attracting In-
dian experts who are currently active in this field in developed
countries. Members of the Indian scientific diaspora (expatriates
working in industrially developed countries) have begun to return
to India in greater numbers, encouraged by economic prosperity
and active recruitment initiatives from firms and research insti-
tutes. More proactive strategies could strengthen this flow of
returning scientists, with targeted efforts designed to attract
expatriate experts in stem cell research.
Increasing Public Awareness
While Indians who have heard of stem cell research and thera-
pies are generally supportive, this field is still relatively unknown
to the general public, except to a small subpopulation of edu-
cated urbanites. There is some risk that this lack of broad under-
standing may lead to uninformed mistrust of the field, particularly
if scandals or slow results help to destroy public support and
lead Indians to mobilize against new stem cell therapies. This
mobilization against new technologies has already occurred in
India with the introduction of genetically modified cotton
(Padma, 2006). While this risk is not unique to India, it is particu-
larly challenging to educate the extensive Indian population
about stem cells, due to the logistical difficulty of communicating
the details of scientific advances to a vast population with typi-
cally low levels of general education. Another risk that is not14 Cell Stem Cell 3, July 2008 ª2008 Elsevier Inc.specific to India, but that might be unusually challenging to over-
come in this country, is that expectations for stem cell-based
therapies may be overly inflated to the ultimate detriment of
the field. There is considerable potential for the exploitation of
patients who see stem cell therapy as a ‘‘magic bullet’’ to solve
their health needs. This exploitation has already been described
in anecdotes of Indian clinics offering stem cell therapies without
a strong scientific basis or proper safety and efficacy tests. Pub-
lic education about the current and future potential of stem cell
therapies should decrease uninformed mistrust of stem cell
therapies and reduce the potential for patient exploitation. As
in most countries, there is as yet no public initiative in India aimed
at stem cell education, something that the Indian government
should take steps to change.
Developing the Regulatory Framework
Until recently, India lacked comprehensive stem cell research
and therapy guidelines, an omission that compounded the
potential for patient exploitation. Uncertainty over which stem
cell scientific research areas could ultimately be seen as legally
and ethically acceptable also discouraged cautious researchers
from entering the field. To address this barrier, ICMR led the
development of stem cell research and therapy guidelines (see
ICMR National Guidelines) with the participation of DBT and
others. Newly finalized, the guidelines are relatively permissive,
allowing hESC and adult stem cell research and cell line develop-
ment under close monitoring. Experimental treatments, embryo
creation for research, and chimera studies are permissible sub-
ject to approval. The guidelines create two levels of stem cell re-
search review and monitoring: a National Apex Committee for
Stem Cell Research and Therapy as well as institutional commit-
tees. Depending on the research topic, projects will be approved
nationally or institutionally; research will be categorized into
permissive, restricted, and prohibitive areas for research, and
all projects will have to register nationally. India’s guidelines
are relatively permissive when compared to other countries. Re-
garding hESC research, one study surveyed 50 countries and
found that hESC research was allowed under strict conditions
in 23 countries and banned in five, while the rest had no explicit
policy (Isasi and Knoppers, 2006). The new Indian guidelines are
not legally binding; however, many Indians remain optimistic that
their existence will encourage researchers to begin working in
the area of stem cells while simultaneously stopping unethical
R&D. It’s unclear how successful the guidelines’ implementation
will be. India has a poor track record at monitoring IVF clinics and
enforcing its guidelines for biomedical research using human
subjects (Salter et al., 2007). With hospitals and clinics already
initiating stem cell-based trials and experimental procedures,
the Indian government needs to proactively enforce its new
guidelines. If it fails to do so, a poor stem cell regulatory frame-
work may become a significant hindrance to the field’s develop-
ment, particularly as related to international collaborations and
commercial links.
Concluding Thoughts
Much of the interest in stem cell research and therapies in India
appears focused on patient need, particularly the growing na-
tional burden of chronic diseases such as diabetes and myocar-
dial infarction, for which stem cell therapies may offer promising
solutions. While stem cell therapies do have the potential to
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ments will be accessible to most Indians. As the LVPEI ocular
surface reconstruction work illustrates, affordable stem cell-
based treatments can be developed. It may be that stem cell
therapies developed in India would cost less than treatments de-
veloped in industrialized countries due to India’s low R&D cost
and process engineering advantages. Moreover, because stem
cell therapies can potentially be applied to cure chronic diseases
such as diabetes that require lifelong treatment, the cost of
a stem cell therapy may be less than cumulative conventional
treatment costs, at least in some cases. However, the initial
costs of most stem cell treatments will likely be high. Health in-
surance remains limited in India, and private households account
for more than 80% of total health spending in the nation (National
Commission on Macroeconomics and Health). Many Indians
cannot afford even basic health care, and relatively established
stem cell treatments such as bone marrow transplants are be-
yond the budget of a significant number of the Indian population
that can pay for standard care (Kanga et al., 2007). Several hos-
pitals in India do charity work or charge based on patient income.
This approach will likely provide a means to bring stem cell ther-
apies to the Indian population, but not at a meaningful scale. As
the technology matures, treatments may become more afford-
able. Only time will tell whether stem cell therapies, as they
develop, will become a widely available treatment option for
India’s poor.
As India’s capacity in stem cell research continues to develop,
it can draw upon the nation’s numerous strengths to actively
expand its involvement in this field. Based on its track record
in information technologies and biotechnology, it is likely that
India will be successful in building its capacity for implementing
stem cell therapies. To address current barriers to this sector,
India needs to further increase integration between researchers
and clinicians, foster high-quality education and training, in-
crease public awareness, and secure adherence to its new
stem cell regulatory framework. India must also build on its cur-
rent strengths by leveraging the vast and diverse population,
government resources, and past entrepreneurial experience in
clinical trials and treatment development. By taking additional
steps in this direction, India will not only be successful in har-
nessing stem cells to improve the health of its population but is
likely to become one of the main contributors to this emerging
field. As Professor D. Balasubramanian, director of research at
the LVPEI, questioned: ‘‘So, how many years are we behind?
Five years behind? Four years behind? Why can’t we catch
up?’’ India’s current and future successes within stem cell R&D
provide an example for other developing countries and demon-
strate that cutting edge science can be applied successfully to
improve health in the developing world. The situation in India
also conveys to the rest of the world that the innovation
landscape is changing and that the contributions made by
emerging economies to the stem cell field must not be ignored
or overlooked.
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